Pharmac’s decision to fund immunotherapy treatment durvalumab (imfinzi) for stage 3 lung cancer is a small step forward. Lung Foundation New Zealand (LFNZ) acknowledges the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting durvalumab (imfinzi) across the line. This funding decision also highlights extreme inequities with access to treatments […]
2022
Respiratory Research Review Features Lung Cancer
Lung Foundation New Zealand (LFNZ) really values the collaboration our cause has with Research Review. We’re pleased to publish the latest issue of Respiratory Research Review which focuses on Lung Cancer. Respiratory_Research_Review_Issue_193_Lung_Cancer
New research to focus on inequity in lung cancer
While, Lung Foundation New Zealand (LFNZ) endorses the funding decision and we applaud the efforts of the researchers that dedicate their life to improving health policy, providing lung cancer patients access to more treatment options NOW, will prevent premature death and eliminate inequities. https://www.rnz.co.nz/news/national/459893/new-research-fund-to-focus-on-inequity-in-lung-cancer-treatment-diagnosis
